SCHEMBL3874255

SCHEMBL3874255

Cc1cc(NCCO)c2c(c1N)c1ccccc1n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.43
MAPT P10636 2/20 0.43
CYP2C19 P33261 1/20 0.40
ALKBH5 Q6P6C2 1/20 0.38
FTO Q9C0B1 1/20 0.38
GABRP O00591 4/20 0.37
GABRD O14764 4/20 0.37
GABRA1 P14867 4/20 0.37
GABRB1 P18505 4/20 0.37
GABRG2 P18507 4/20 0.37
GABRB3 P28472 4/20 0.37
GABRA5 P31644 4/20 0.37
GABRA3 P34903 4/20 0.37
GABRA2 P47869 4/20 0.37
GABRB2 P47870 4/20 0.37
GABRA4 P48169 4/20 0.37
GABRE P78334 4/20 0.37
GABRA6 Q16445 4/20 0.37
GABRG1 Q8N1C3 4/20 0.37
GABRG3 Q99928 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885326 0.93 KDM4E (0.42) KDM4EMAPTALKBH5FTOGABRP
SCHEMBL3872755 0.87 KDM4E (0.48) KDM4EMAPTALKBH5FTOGABRP
SCHEMBL3878943 0.81 KDM4E (0.43) KDM4EMAPTCYP2C19ALKBH5FTO
SCHEMBL27653219 0.81 KDM4E (0.42) KDM4EMAPTALKBH5FTOGABRP
SCHEMBL3884371 0.79 KDM4E (0.40) KDM4EMAPTCYP2C19ALKBH5FTO
SCHEMBL3882537 0.77 KDM4E (0.43) KDM4EMAPTALKBH5FTOGABRP
SCHEMBL3877123 0.76 KDM4E (0.56) KDM4EMAPTALKBH5FTOGABRP
SCHEMBL3874922 0.76 KDM4E (0.43) KDM4EMAPTALKBH5FTOGABRP
SCHEMBL3882739 0.74 NQO2 (0.44) KDM4EMAPTHSD17B10NQO2MEN1
SCHEMBL3874903 0.72 TERT (0.43) KDM4EMAPTCYP2C19RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080098535-A1 Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof GLENN ROBERT W JR 2008-05-01 US claimed
US-20050217038-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof PROCTER & GAMBLE COMPANY, THE 2005-10-06 US claimed
US-7491245-B2 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof THE PROCTER & GAMBLE COMPANY (US) 2009-02-17 US disclosed
US-20080098535-A1 Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof GLENN ROBERT W JR 2008-05-01 US disclosed
US-7331997-B2 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof THE PROCTER & GAMBLE COMPANY (US) 2008-02-19 US disclosed
EP-1735059-A2 KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF The Procter and Gamble Company (US) 2006-12-27 EP disclosed
WO-2005099656-A2 KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF THE PROCTER & GAMBLE COMPANY (US) 2005-10-27 WO disclosed
US-20050217038-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof PROCTER & GAMBLE COMPANY, THE 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050217038-A1 Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof KRT18, CKMT1A; CKMT1B, TUBB6 KDM4E 1549/4885MAPT 420/4885CYP2C19 1869/4885
US-20080098535-A1 Keratin Dyeing Compounds, Keratin Dyeing Compositions Containing Them, And Use Thereof KRT18, CKMT1A; CKMT1B, TUBB6 KDM4E 1549/4885MAPT 420/4885CYP2C19 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.